Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BECC-adjuvanted L-SseB nanoparticle vaccine
- Development stage
- Preclinical
- Lead developer
- TollereBio
- Modality
- Vaccines & Immunotherapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular, Intranasal
01
Overview
TollereBio is developing a vaccine candidate for the prevention of Salmonella infection, currently in the preclinical stage. The vaccine utilizes a nanoparticle formulation that incorporates the Salmonella protein L-SseB as an antigen. To enhance the immune response, the formulation includes a BECC (Bacterial Enzymatic Combinatorial Chemistry) adjuvant, which functions as a Toll-like receptor 4 (TLR4) agonist. This combination is designed to stimulate robust anti-Salmonella immunity by leveraging both a specific bacterial antigen and a potent innate immune activator.
- Other names
- Salmonella vaccineL-SseB nanoparticle vaccineSalmonella
02
Targets
TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on BECC-adjuvanted L-SseB nanoparticle vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BECC-adjuvanted L-SseB nanoparticle vaccine.